Fostamatinib, a widely used RIPK1 inhibitor in clinical practice, has shown promising results in a randomized trial for the treatment of immune thrombocytopenia (ITP), demonstrating clinically significant responses in patients [52]. This evidence concerns the gene RIPK1 and autoimmune thrombocytopenic purpura.